Liraglutide and exenatide, two GLP-1 RAs, may improve skeletal blood supply, increase bone mineral density (BMD), and reduce the risk of osteoporosis and fracture in animal and human studies [27, 50]. The gene discussed is GLP1R; the disease is osteoporosis.